(KRO) Kronos Worldwide - Overview
Stock: Titanium Dioxide, Ilmenite, Iron Chemicals, Specialty Chemicals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.33% |
| Yield on Cost 5y | 1.75% |
| Yield CAGR 5y | -27.40% |
| Payout Consistency | 80.5% |
| Payout Ratio | 33.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 50.7% |
| Relative Tail Risk | -8.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.68 |
| Alpha | -53.04 |
| Character TTM | |
|---|---|
| Beta | 1.308 |
| Beta Downside | 0.812 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.73% |
| CAGR/Max DD | -0.20 |
Description: KRO Kronos Worldwide December 24, 2025
Kronos Worldwide Inc. (NYSE:KRO) is a Dallas-based subsidiary of Valhi, Inc. that manufactures titanium dioxide (TiO₂) pigments for a broad range of end-markets, including paints, coatings, plastics, paper, fibers, ceramics, inks, foods, cosmetics, and pharmaceuticals.
The company produces TiO₂ in both rutile and anatase crystalline forms and also supplies ilmenite feedstock, iron-based chemicals for water treatment and pigment production, and specialty chemicals used in pearlescent pigments, electro-ceramic capacitors, and natural-gas pipe applications. Technical services complement its product offerings.
Kronos sells its portfolio under the KRONOS brand through a global network of agents and distributors, serving customers in Europe, North America, the Asia-Pacific region, and other international markets.
Recent data (2023) show revenue of roughly $1.1 billion with an adjusted EBITDA margin near 12%, while the TiO₂ price index rose about 8% year-over-year, reflecting strong demand from the construction and automotive paint sectors. A key industry driver is the ongoing shift from sulfate-process to lower-emission chloride-process TiO₂ production, which could pressure margins for pure-sulfate producers.
For a deeper quantitative view of Kronos’s valuation metrics and peer comparisons, you might find a quick look at ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -41.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -6.59 > 1.0 |
| NWC/Revenue: 42.44% < 20% (prev 35.92%; Δ 6.53% < -1%) |
| CFO/TA -0.02 > 3% & CFO -40.3m > Net Income -41.3m |
| Net Debt (619.4m) to EBITDA (118.7m): 5.22 < 3 |
| Current Ratio: 3.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 16.25% > 18% (prev 0.18%; Δ 1608 % > 0.5%) |
| Asset Turnover: 97.31% > 50% (prev 97.01%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: 1.13 > 6 (EBITDA TTM 118.7m / Interest Expense TTM 50.6m) |
Altman Z'' 1.92
| A: 0.41 (Total Current Assets 1.07b - Total Current Liabilities 279.2m) / Total Assets 1.91b |
| B: -0.13 (Retained Earnings -256.4m / Total Assets 1.91b) |
| C: 0.03 (EBIT TTM 57.0m / Avg Total Assets 1.92b) |
| D: -0.53 (Book Value of Equity -585.7m / Total Liabilities 1.10b) |
| Altman-Z'' Score: 1.92 = BBB |
Beneish M -3.12
| DSRI: 0.91 (Receivables 334.3m/366.5m, Revenue 1.86b/1.86b) |
| GMI: 1.08 (GM 16.25% / 17.62%) |
| AQI: 0.84 (AQ_t 0.05 / AQ_t-1 0.06) |
| SGI: 1.00 (Revenue 1.86b / 1.86b) |
| TATA: -0.00 (NI -41.3m - CFO -40.3m) / TA 1.91b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of KRO shares?
Over the past week, the price has changed by +15.81%, over one month by +23.08%, over three months by +30.32% and over the past year by -34.87%.
Is KRO a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the KRO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.5 | -9.5% |
| Analysts Target Price | 5.5 | -9.5% |
| ValueRay Target Price | 6 | -1% |
KRO Fundamental Data Overview February 03, 2026
P/B = 0.7692
P/EG = -0.53
Revenue TTM = 1.86b USD
EBIT TTM = 57.0m USD
EBITDA TTM = 118.7m USD
Long Term Debt = 626.2m USD (from longTermDebt, last quarter)
Short Term Debt = 4.40m USD (from shortTermDebt, last quarter)
Debt = 647.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 619.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.22b USD (604.0m + Debt 647.1m - CCE 27.7m)
Interest Coverage Ratio = 1.13 (Ebit TTM 57.0m / Interest Expense TTM 50.6m)
EV/FCF = -19.70x (Enterprise Value 1.22b / FCF TTM -62.1m)
FCF Yield = -5.08% (FCF TTM -62.1m / Enterprise Value 1.22b)
FCF Margin = -3.33% (FCF TTM -62.1m / Revenue TTM 1.86b)
Net Margin = -2.22% (Net Income TTM -41.3m / Revenue TTM 1.86b)
Gross Margin = 16.25% ((Revenue TTM 1.86b - Cost of Revenue TTM 1.56b) / Revenue TTM)
Gross Margin QoQ = 10.29% (prev 12.70%)
Tobins Q-Ratio = 0.64 (Enterprise Value 1.22b / Total Assets 1.91b)
Interest Expense / Debt = 2.18% (Interest Expense 14.1m / Debt 647.1m)
Taxrate = 42.38% (63.4m / 149.6m)
NOPAT = 32.8m (EBIT 57.0m * (1 - 42.38%))
Current Ratio = 3.83 (Total Current Assets 1.07b / Total Current Liabilities 279.2m)
Debt / Equity = 0.80 (Debt 647.1m / totalStockholderEquity, last quarter 804.7m)
Debt / EBITDA = 5.22 (Net Debt 619.4m / EBITDA 118.7m)
Debt / FCF = -9.97 (negative FCF - burning cash) (Net Debt 619.4m / FCF TTM -62.1m)
Total Stockholder Equity = 828.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.16% (Net Income -41.3m / Total Assets 1.91b)
RoE = -4.98% (Net Income TTM -41.3m / Total Stockholder Equity 828.9m)
RoCE = 3.92% (EBIT 57.0m / Capital Employed (Equity 828.9m + L.T.Debt 626.2m))
RoIC = 2.35% (NOPAT 32.8m / Invested Capital 1.40b)
WACC = 5.83% (E(604.0m)/V(1.25b) * Re(10.73%) + D(647.1m)/V(1.25b) * Rd(2.18%) * (1-Tc(0.42)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -62.1m)
EPS Correlation: -47.13 | EPS CAGR: -21.63% | SUE: 0.94 | # QB: 1
Revenue Correlation: -8.83 | Revenue CAGR: -2.17% | SUE: -0.24 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=-0.160 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.07 | Chg30d=-0.363 | Revisions Net=-1 | Growth EPS=+116.1% | Growth Revenue=+5.0%